TLS in Tumors: What Lies Within

0 avis

TLS in Tumors: What Lies Within

Archive ouverte

Sautès-Fridman, Catherine | Fridman, Wolf Herman

International audience. The role of tertiary lymphoid structures (TLS) in cancer has recently been illustrated and revisited using mouse models. Joshi et al. describe regulatory T (Treg) cell infiltration and functional heterogeneity of TLS in lung tumors. Finkin et al. report that inflammation-associated TLS serve as niche for tumor progenitor cells, which may lead to recurrence in hepatocellular-carcinoma.

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Archive ouverte | Vano, Yann-Alexandre | CCSD

International audience. Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensi...

Timing and location dictate monocyte fate and their transition to tumor-associated macrophages

Archive ouverte | Dunsmore, Garett | CCSD

International audience. Tumor-associated macrophages (TAMs) are a heterogeneous population of cells whose phenotypes and functions are shaped by factors that are incompletely understood. Herein, we asked when and wh...

Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment

Archive ouverte | Ben Abdelwahed, Rym | CCSD

International audience. Toll-like receptor (TLR) agonists have important properties that can be exploited for immunotherapy against tumors. Locally injected immunostimulatory oligodeoxynucleotides containing CpG mot...

Chargement des enrichissements...